AUPH - (Aurinia Pharmaceuticals Inc)

 AUPHのチャート


 AUPHの企業情報

symbol AUPH
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種   
概要 事業概要 --     Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/auph
adr_tso
EBITDA EBITDA ー
終値(lastsale) 6.1601
時価総額(marketcap) 525599241.0367
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 AUPHのテクニカル分析


 AUPHのニュース

   Shark Bites: Positioning for a Positive Catalyst in Aurinia Pharmaceuticals  2020/10/05 17:30:00 The Street RealMoney
AUPH has two very large market opportunities for its voclosporin drug….AUPH
   Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome  2020/09/28 10:05:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune conditions, today announced that the last patient study visit has occurred in the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing vi
   Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2020/09/04 22:04:00 Business Wire
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified stock options to purchase an aggregate of 530,000 common shares, at a per share exercise price of $14.83 USD, the closing trading price on August 31,
   Recap: Aurinia Pharmaceuticals Q2 Earnings  2020/08/11 17:29:00 Benzinga
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) were unchanged after-market trading after the company reported Q2 results. Quarterly Results Earnings …
   Aurinia Pharmaceuticals : to Present at the BTIG Virtual Biotechnology Conference | MarketScreener  2020/08/04 10:06:03 MarketScreener
Aurinia Pharmaceuticals Inc. today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference… | August 4, 2020
   Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference  2020/05/15 20:05:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 RBC Capital Markets’ Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 10:20 a.m. E.D.T. In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” se
   Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Q1 2020 Earnings Call Transcript  2020/05/15 13:06:38 news.alphastreet.com
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2020 earnings call dated May. 14, 2020 Corporate Participants: Glenn Schulman — Head of Investor Relations and Corporate Communications Peter Greenleaf — Chief Executive Officer and Director Neil Solomons — Chief Medical Officer Max Colao — Chief Commercial Officer Joe Miller — Chief Financial Officer Michael Martin — Chief Operating Officer Analysts: Alethia Young — Cantor Fitzgerald — Analyst Ken Cacciatore — Cowen — Analyst Joseph […]
   Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Misses Revenue Estimates  2020/05/14 21:35:05 Zacks Investment Research
Aurinia (AUPH) delivered earnings and revenue surprises of 25.00% and -50.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights  2020/05/14 20:02:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars. “We are fortunate that the global COVID-19 pandemic has had minimal impact on Aurinia’s operations, and we have maintained our timelines to ensure the filing of the voclo
   Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland  2020/03/17 10:00:00 Business Wire
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia established U.S. Center of Commercial Operations in Rockville, MD
   Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock  2020/01/23 14:11:00 Zacks Investment Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
   My Top Stock Pick for 2020 Is a Super Strong Finisher From 2019  2020/01/02 17:00:00 TheStreet
James "Rev Shark" DePorre's top stock pick for 2020 is a super strong finisher from 2019; it's Aurinia Pharmaceuticals, which has solid upside potential as it starts the process of commercializing its drugs, and it could be acquired to boot….AUPH
   The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data  2019/12/18 12:23:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Medtronic PLC (NYSE: MDT )(announced acquisition of Klue, a software company focused on behavior tracking) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nantkwest Inc (NASDAQ: NK ) Novo Nordisk A/S (NYSE: NVO ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) NuVasive, Inc. (NASDAQ: NUVA ) Ovid Therapeutics Inc (NASDAQ: OVID ) Prevail Therapeutics Inc (NASDAQ: PRVL )( announced Orphan Drug Designation for its dementia asset) Principia Biopharma Inc (NASDAQ: PRNB ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) ResMed Inc. (NYSE: RMD ) Soligenix, Inc.
   The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer  2019/12/13 13:10:02 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.
   Aurinia Pharmaceuticals sells $191.7-million in public offering of shares after positive trial results for lupus drug  2019/12/13 03:05:09 The Globe and Mail
The Victoria-based biotech developer announced early Monday that it is planning to sell US$150-million of stock to fund pre-commercialization and launch activities for its drug voclosporin

 関連キーワード  (― 米国株 AUPH Aurinia Pharmaceuticals Inc)

 twitter  (公式ツイッターやCEOツイッターなど)